$1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study of Enhanced Antibody for Treatment of Acute Myeloid Leukemia
OXFORD, England and BERLIN, November 25, 2014 /PRNewswire/ --
Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis
Janssen Submits New Drug Application for YONDELIS® (trabectedin) to U.S. FDA for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Novartis announces extension to FDA review period for multiple myeloma investigational compound LBH589
Biotech Stocks in Motion - Amgen, Merrimack Pharma, NPS Pharma, BioMarin Pharma, and Regeneron Pharma
Editor Note: For more information about this release, please scroll to bottom.
LONDON, November 24, 2014
NEW YORK, Nov.